Company Description
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.
The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.
It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases.
The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.
Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
| Country | United States |
| IPO Date | Oct 12, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 45 |
| CEO | Bruce D. Steel C.F.A. |
Contact Details
Address: 2223 Avenida De La Playa La Jolla, California United States | |
| Website | https://equilliumbio.com |
Stock Details
| Ticker Symbol | EQ |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001746466 |
| CUSIP Number | 29446K106 |
| ISIN Number | US29446K1060 |
| Employer ID | 82-1554746 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Bruce D. Steel C.F.A. | Co-Founder, President, Chief Executive Officer & Director |
| Christine Zedelmayer M.B.A., P.M.P. | Senior Vice President & Chief Operating Officer |
| Jason A. Keyes | Chief Financial Officer |
| Daniel Mark Bradbury | Executive Chairman |
| Dr. Matthew Ritter Ph.D. | Senior Vice President of Corporate Development |
| Dr. Stephen Connelly Ph.D. | Chief Scientific Officer & Director |
| Joel M. Rothman | Chief Development Officer |
| Michael Moore | Vice President of Investor Relations & Corporate Communications |
| Penny Tom | Senior Vice President of Finance & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 13, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 4 | Filing |
| Dec 12, 2024 | 3 | Filing |
| Dec 12, 2024 | 8-K | Current Report |
| Nov 15, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Nov 13, 2024 | 8-K | Current Report |
| Oct 31, 2024 | 8-K | Current Report |
| Oct 30, 2024 | 4 | Filing |